CN106420772B - 一种治疗急性胰腺炎的药物组合物 - Google Patents
一种治疗急性胰腺炎的药物组合物 Download PDFInfo
- Publication number
- CN106420772B CN106420772B CN201610819356.7A CN201610819356A CN106420772B CN 106420772 B CN106420772 B CN 106420772B CN 201610819356 A CN201610819356 A CN 201610819356A CN 106420772 B CN106420772 B CN 106420772B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- acute pancreatitis
- present
- treating acute
- steroid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010033645 Pancreatitis Diseases 0.000 title claims abstract description 21
- 206010033647 Pancreatitis acute Diseases 0.000 title claims abstract description 18
- 201000003229 acute pancreatitis Diseases 0.000 title claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 12
- 150000003431 steroids Chemical class 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 239000003937 drug carrier Substances 0.000 abstract description 4
- 150000003839 salts Chemical class 0.000 abstract description 4
- 229940002612 prodrug Drugs 0.000 abstract description 3
- 239000000651 prodrug Substances 0.000 abstract description 3
- 239000012453 solvate Substances 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 2
- 208000024691 pancreas disease Diseases 0.000 abstract description 2
- 210000002381 plasma Anatomy 0.000 description 7
- 210000000496 pancreas Anatomy 0.000 description 6
- 229910002651 NO3 Inorganic materials 0.000 description 5
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 108090000913 Nitrate Reductases Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- -1 antiseptic Substances 0.000 description 2
- 210000003445 biliary tract Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610819356.7A CN106420772B (zh) | 2016-09-13 | 2016-09-13 | 一种治疗急性胰腺炎的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610819356.7A CN106420772B (zh) | 2016-09-13 | 2016-09-13 | 一种治疗急性胰腺炎的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106420772A CN106420772A (zh) | 2017-02-22 |
CN106420772B true CN106420772B (zh) | 2017-07-28 |
Family
ID=58167664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610819356.7A Expired - Fee Related CN106420772B (zh) | 2016-09-13 | 2016-09-13 | 一种治疗急性胰腺炎的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106420772B (zh) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102558278B (zh) * | 2010-12-28 | 2014-07-09 | 复旦大学 | 三萜类化合物及其在制备抗补体药物中的用途 |
CN102408466B (zh) * | 2011-12-22 | 2014-05-14 | 江苏省中国科学院植物研究所 | 一种新盐角草皂苷及其制备方法和用途 |
-
2016
- 2016-09-13 CN CN201610819356.7A patent/CN106420772B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN106420772A (zh) | 2017-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101716176A (zh) | 一种注射用右兰索拉唑及其制备方法 | |
CN103720701A (zh) | 在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法 | |
CN106420772B (zh) | 一种治疗急性胰腺炎的药物组合物 | |
WO2012079203A1 (zh) | 一种葛根素水合物、其制备方法及用途 | |
WO2017079566A1 (en) | Caspase inhibitors for use in the treatment of liver cancer | |
CN101513387A (zh) | 埃索美拉唑镁注射液 | |
US20210308192A1 (en) | Composition for preventing or treating ischemic enteritis containing dna fragment mixture isolated from sperm or testis of fish | |
BR112021000279A2 (pt) | Formulações de redução de tumor e métodos de uso das mesmas | |
Chen et al. | Mitochondrial dysfunction in the pathogenesis of acute pancreatitis | |
DE112018005145T5 (de) | Hemmung von aminoacylase 3 (aa3) bei der behandlung von krebs | |
Rock et al. | Suppression of lithium chloride-induced conditioned gaping (a model of nausea-induced behaviour) in rats (using the taste reactivity test) with metoclopramide is enhanced by cannabidiolic acid | |
EP2698155A1 (en) | Pharmaceutical unit dosage form comprising 4-phenylbutyric acid | |
JP6051315B2 (ja) | 乾癬を処置するためのピドチモドの使用 | |
CN106474097B (zh) | 抗癌剂 | |
Mudhol et al. | Mitomycin C in ophthalmology | |
KR102076263B1 (ko) | 셀레노사마필린 a를 유효성분으로 포함하는 유방암 예방 및 치료용 조성물 | |
Canedo et al. | Pulmonary effects after partial liver ischemia and reperfusion: experimental model | |
CN107496426A (zh) | 含伊马替尼或其药学上可接受的盐作为有效成分的用于治疗或预防血管渗透性疾病的组合物 | |
RU2581022C1 (ru) | Противоопухолевые фармацевтические композиции и способ лечения рака молочной железы | |
WO2019226349A1 (en) | Oral composition of citrus pectin and papain to decrease plasma free igf-1 levels in individuals who need it and methods of preparation in soft capsule and syrup dosage forms | |
Dumitru | Medical treatment of cystic echinococcosis | |
CN107823207B (zh) | 一种治疗动脉粥样硬化的口服药物组合物 | |
CN105963287B (zh) | 复方组合物及其医药用途 | |
CN106511344A (zh) | 一种胃酸分泌抑制剂的新用途 | |
JP5872769B2 (ja) | 冬虫夏草菌糸体抽出物を有効成分として含む移植片拒絶抑制用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Guo Lei Inventor after: Dong Hui Inventor after: Wang Song Inventor after: Wang Xie Inventor after: Tian Deyong Inventor before: Wang Fang |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20170630 Address after: 430030, Zhenxing Avenue, Dongxihu District, Hubei, Wuhan province 1 Applicant after: Wuhan Junan Pharmaceutical Co.,Ltd. Address before: 200040 Shanghai Pharmaceutical Industry Research Institute, No. 1320 West Beijing Road, Shanghai, Jingan District Applicant before: Wang Fang |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170728 |
|
CF01 | Termination of patent right due to non-payment of annual fee |